Abstract: BCOR-CCNB3 sarcoma (BCS) is a recently defined genetic entity among undifferentiated round cell sarcomas, which was initially classified as and treated similarly to the Ewing sarcoma (ES) family of tumors. In contrast to ES, BCS shows consistent BCOR overexpression, and preliminary evidence suggests that these tumors share morphologic features with other tumors harboring BCOR genetic alterations, including BCOR internal tandem duplication (ITD) and BCOR-MAML3. To further investigate the pathologic features, clinical behavior, and their relationship to other round cell sarcomas, we collected 36 molecularly confirmed BCSs for a detailed histologic and immunohistochemical analysis. Four of the cases were also analyzed by RNA sequencing (RNAseq). An additional case with BCOR overexpression but negative CCNB3 abnormality showed a novel KMT2D-BCOR fusion by targeted RNAseq. The patients ranged in age from 2 to 44 years old (mean and median, 15), with striking male predominance (M:F = 31:5). The tumor locations were slightly more common in bone (n = 20) than soft tissue (n = 14), with rare visceral (kidney, n = 2) involvement.
B
COR-CCNB3 sarcomas (BCSs) were first identified by Pierron et al 1 in 2012 among a large group of undifferentiated round cell sarcomas lacking known genetic alterations through whole transcriptome sequencing and subsequent reverse transcription-polymerase chain reaction (RT-PCR) screen. The genetic abnormality involves a paracentric inversion on the short arm of chromosome X, resulting in the fusion of 2 nearby genes BCOR and CCNB3 (10 Mb apart) and leading to the overexpression of CCNB3. This initial study showed that BCS occurs with predilection in male adolescents and skeletal locations and has a primitive round cell morphology reminiscent of Ewing sarcomas (ESs). 1 Two subsequent smaller series of 10 and 6 cases, respectively, pointed out these tumors harbor a mixed round to spindle cell morphology and are evenly distributed between bone and soft tissue sites. 2, 3 On the basis of these findings, the differential diagnosis of BCS is quite challenging, including not only tumors in the ES family but also undifferentiated spindle cell sarcomas, such as synovial sarcomas (SSs) and malignant peripheral nerve sheath tumors (MPNST). Because of the common presentation within bone, BCS can be further confused with small cell osteosarcoma. Thus, in most cases a molecular diagnosis demonstrating the presence of BCOR-CCNB3 fusion is required for a more definitive diagnosis. More recently, emerging evidence suggested that tumors with BCOR genetic abnormalities, including BCOR-CCNB3, BCOR-MAML3, and BCOR internal tandem duplications (ITDs) share significant overlap not only at the gene expression level, due to BCOR upregulation, but also morphologically. 4 This study sets out to define the morphologic and immunohistochemical spectrum of a large cohort of molecularly confirmed BCS and evaluate features that overlap with other members of the so-called "BCOR family of tumors." Furthermore, as these tumors have been managed with similar chemotherapy regimens to those used in ES, we also examined the therapy-related pathologic response in our cohort and compared the survival of the BCS study group to individual cohorts of molecularly defined ES, CIC-DUX4 sarcoma, and SS.
MATERIALS AND METHODS

Study Cohort
The Surgical Pathology files of MSKCC as well as the consultation files of the senior authors (C.R.A., C.D. M.F., and B.C.D.) were searched for primitive round and spindle cell sarcomas that had molecular confirmation of BCOR-CCNB3 fusion by fluorescence in situ hybridization (FISH) or RNA sequencing (RNAseq). Hematoxylin and eosin-stained slides were reviewed. Cases without available material for review were excluded. Three cases were reported previously (cases 18, 21, 27) . 5, 6 The study group was analyzed for demographic information, anatomic site, tumor size, and morphologic features, including cell type (round, spindle, mixed), degree of cellularity, type and amount of stromal component, nuclear features, mitotic activity, and presence of necrosis. Available immunohistochemical stains were reviewed, including BCOR, SATB2, cyclin D1, TLE1, Bcl-2, and CD99. The clinical follow-up information was obtained from review of the electronic medical records and from contacting referring pathologists and clinicians. The study was approved by the institutional review board.
Fluorescence In Situ Hybridization
FISH for BCOR-CCNB3 fusions was performed on 4 μm formalin-fixed paraffin-embedded tissue sections in 34 cases. Custom FISH probes were prepared using bacterial artificial chromosomes flanking BCOR (telomeric: RP11-21D3, RP11-1105N2; centromeric: RP11-37K20, RP11-973F20) and CCNB3 (telomeric: RP11-58H17; centromeric: RP11-168F22, RP11-96H3). The FISH procedure was performed as previously described. 7 
RNA Sequencing
One and 3 cases were submitted to whole transcriptome sequencing (case 19) and targeted RNAseq (cases 8, 21, 35) , respectively. For whole transcriptome sequencing, total RNA was extracted from frozen tissues using RNeasy Plus Mini (Qiagen), followed by mRNA isolation with oligo(dT) magnetic beads and fragmentation by incubation at 94°C in fragmentation buffer (Illumina, San Diego, CA) for 2.5 minutes. After gel size selection (350 to 400 bp) and adapter ligation, the library was enriched by PCR for 15 cycles and purified. Pairedend RNAseq at read lengths of 50 or 51 bp was performed with the HiSeq 2000 (Illumina). For targeted RNAseq, RNA was extracted from FFPE tissue using Amsbio's ExpressArt FFPE Clear RNA Ready kit (Amsbio LLC, Cambridge, MA). Fragment length was assessed with an RNA 6000 chip on an Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA). RNAseq libraries were prepared using 20 to 100 ng total RNA with the Trusight RNA Fusion Panel (Illumina), which targets a list of 507 genes of interest. Targeted RNAseq was performed on an Illumina MiSeq platform. Reads were independently aligned with STAR (version 2.3) against the human reference genome (hg19) and analyzed by STAR-Fusion.
Reverse Transcription Polymerase Chain Reaction
RT-PCR was performed in case 19 to validate the fusion transcript identified by RNAseq. RNA was extracted from frozen tissues by RNeasy Plus Mini (Qiagen) and reverse transcribed by SuperScript IV First-Strand Synthesis System (Invitrogen). PCR was performed by Advantage 2 PCR kit (Clontech, Mountain View, CA). Forward BCOR primer (5'-GACCTGGAAGCCTT-CAACCC) and reverse CCNB3 primer (5'-GAAGAGA-GATGCCTCCTCAGTG) were used. The reaction was run at an annealing temperature of 66°C for 35 cycles.
Expression Profile Analysis by Affymetrix U133A Plus 2 Array
To compare the expression profile of BCSs with morphologically similar tumors, including ES and SS, we have downloaded publicly available expression array data from GEO, including: 10 BCS (GSE34800) and 4 ES (GSE34800) from the study by Pierron et al, 1 34 SS (GSE20196), 8 and a control group of normal tissues (GSE7307) on Affymetrix Human Genome U133A Plus 2 platform. Gene signatures of each tumor entity were obtained by comparing to the control group of normal tissues, using log2-fold change threshold of positive 3 and negative 5, FDR 0.01. A Venn diagram was used to assess the relationship among these gene signatures. Supervised clustering was performed using the gene signature specific for each group.
Because of the overrepresentation of multiple HOX family genes in the signature of BCS, we further examined the expression of HOX genes in BCS, ES, SS (Affymetrixfold changes between each tumor type compared with the appropriate control groups (normal tissues for the Affymetrix array; various soft tissue tumors for the RNAseq data set) were evaluated in each data set.
Survival Analysis
Follow-up data were available in 22 BCS patients. Statistical analysis was performed on an SPSS platform (version 24.0; IBM Corp., Armonk, NY). The overall survival (OS) time was measured in months from the date of diagnosis to the date of death. Kaplan-Meier estimate was used to calculate the OS. Survival data of 57 CI-C-rearranged round cell sarcomas, 121 ES, and 34 head and neck SS from our previous studies were used for comparison. 9, 10 The OS among different tumors were compared by log-rank analysis. A P-value <0.05 was considered as significant for all statistical analyses.
RESULTS
BCSs Affect Mainly Male Adolescents With Slight Preference for Bone Location
The study cohort of 36 patients showed a striking male predominance (31/36, 86%). The age at presentation ranged from 2 to 44 years old (mean and median, 15) (Table 1) , with 81% of cases occurring between 10 and 20 years of age. The tumor locations were distributed between bone (n = 20) and soft tissue (n = 14), with rare visceral involvement (n = 2). Axial locations and extremities were equally involved. Among skeletal lesions, femur was A indicates doxorubicin/adriamycin; AWD, alive with disease; C, cyclophosphamide; Cp, cisplatin; DOD, dead of disease; DUC, dead of unknown cause; E, etoposide; Er, epirubicin; I, ifosfamide; IT, intra-thecal; M, metastasis; MTX, methotrexate; NA, not available; NED, no evidence of disease; N, no; OS, osteosarcoma; R, recurrence; RT, radiation therapy; TNR, tumor necrosis rate; V, vincristine; VAC-IE, combination of vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide; Y, yes. the most common single site (n = 5), followed by tibia (n = 4), whereas all the axial skeletal tumors involved pelvic bones (3 in sacrum, 2 in ilium, 2 in pubic ramus). Soft tissue lesions occurred within trunk (n = 7), extremities (n = 4), and head and neck (n = 3). Kidney was the only visceral location identified in this cohort. The tumor sizes ranged from 3 to 27 cm (mean, 11.7; median, 11).
BCSs Showed a Wide Morphologic Spectrum Ranging From Round to Spindle Cell Phenotype
The majority of cases (28, 78%) were composed predominantly of primitive round cells, whereas 8 (22%) cases showed mainly spindle cell morphology. Two thirds of BCS with predominant round cell phenotype (19 cases) also had a minor ovoid to spindle cell component, whereas 3 of the 8 predominantly spindle cell BCS showed a minor round cell component. The round cell component had scant cytoplasm and monomorphic nuclei with fine chromatin, indistinct nucleoli, and smooth nuclear contours (Fig. 1A) . The tumor cells were usually arranged in solid hypercellular sheets without a distinct architectural pattern. At the other end of the spectrum were tumors composed predominantly or exclusively of monomorphic spindle cells, commonly arranged in intersecting fascicles (Fig. 1B) and less often in a vague whorling pattern (Fig. 1C) . Most of these spindle cell lesions showed medium to high cellularity, monomorphic, ovoid nuclei with similar fine chromatin pattern. Regardless of the round or spindle cell morphology, most of the tumors showed a rich capillary network (81%). One case revealed alternating low and high cellularity with perivascular condensation, reminiscent of the so-called "marbled pattern" commonly seen in MPNST (Fig. 1D) . Half of the cases showed some degree of myxoid stroma (n = 19, 53%), either loosely separating small nests, cords, or individual tumor cells, or forming a microcystic pattern (Figs. 1E-H) . In some cases, an abrupt transition between hypercellular and hypocellular myxoid areas were noted (Fig. 1I) . A third of cases (n = 13, 36%) showed a more collagenous stroma, either as ropey collagen bundles separating individual tumor cells or as a more confluent collagenous stroma in areas of lower cellularity (Figs. 2A,  B, D-F) . Metaplastic ossification was noted in a metastatic lung lesion in 1 case (Fig. 2C) . Necrosis, either focal or geographic, was present in 16 (44%) cases. Mitotic activity varied significantly, ranging from 1 to 25/10 highpower fields (HPFs) (mean, 8; median, 6).
Two cases showed a deceptively bland and hypocellular spindle cell morphology in the primary lesions, but recurred as highly cellular round cell sarcomas. One of them, a markedly cystic kidney tumor in a 12-year-old male patient, has been reported previously. 6 The other case (case # 20) was a 14-year-old male who presented with a progressively enlarging and tender right fifth toe mass, centered in the soft tissue and showing phalangeal bone destruction. The excised primary lesion was composed of relatively bland-spindle cells with low to medium cellularity, and associated with a collagenous to hyalinized stroma (Figs. 2G-H) . Mitotic activity was low (1/10 HPFs). BCOR immunostaining showed patchy moderate to strong staining (Fig. 2H, inset) . The surgical margin was involved by the tumor and the patient underwent postoperative radiation therapy. One year later, the patient developed a local recurrence involving mainly the phalangeal bone. A wide excision was performed and showed a predominantly round cell sarcoma (Fig. 2I) with only focal spindle cell morphology, similar to the primary lesion. Both the primary and recurrent specimens were positive for BCOR-CCNB3 fusion by FISH.
BCOR-CCNB3 Fusions Identified by FISH and RNAseq
All except 2 cases were tested by FISH using the 3-color BCOR-CCNB3 fusion assay. FISH results typically showed inversions of both BCOR and CCNB3 and fusion of centromeric BCOR (5') to centromeric CCNB3 (3') (Figs. 3A, B) . In some cases, additional unbalanced alterations were observed, such as deletion of telomeric BCOR (3') signals, additional regional breaks, or deletion of the other allele.
Four cases evaluated by RNAseq confirmed the BCOR-CCNB3 fusion, with a similar BCOR exon 15 to CCNB3 exon 5 transcript as previously reported. 1 The fusions were further confirmed by RT-PCR in 1 case (Fig. 3C) . Akin to sarcomas with BCOR-MAML3 and BCOR ITD, the BCOR genetic abnormality consistently involves the end of the last exon of BCOR (exon 15) (Fig. 4A) . 4, 11 Marked mRNA upregulation of the entire BCOR coding sequence was noted in both BCOR-CCNB3 and BCOR ITD tumors (Fig. 4B) . In contrast, CCNB3 mRNA upregulation was noted only in BCS, involving the distal part of the gene, after the exon 5 breakpoint (data not shown). By unsupervised clustering, BCS grouped together with BCOR ITD and BCOR-MAML3 tumors and was separated from ES and CIC-rearranged sarcomas (Fig. 4C) .
A Novel KMT2D-BCOR Identified by Targeted RNAseq in a Recurrent Pelvic Soft Tissue Mass
An additional round cell sarcoma, showing diffuse and strong positivity for BCOR and moderate staining for SATB2, while being negative for BCOR-CCNB3 fusion by FISH, was investigated by targeted RNAseq. The lesion presented as a large pelvic soft tissue mass (size, 11 cm) in a 10-year-old female. Microscopically, the tumor showed a round to short spindle cell phenotype, arranged in short fascicles and whorling pattern. RNAseq identified KMT2D-BCOR gene fusion with multiple breakpoints, including the reciprocal transcript (BCOR-KMT2D). The most abundant fusion junction read was KMT2D exon 42 to the last 173 bp of BCOR exon 4. BCOR mRNA expression was upregulated, especially involving the 3' exons of BCOR gene, distal to the breakpoint, supporting BCOR as the 3' partner. The patient was treated with initial debulking surgery followed by chemotherapy, and subsequent reexcision showed rare microscopic residual foci of viable tumor ( > 90% chemotherapy response). The tumor recurred locally 2 years later.
BCS Shares a Similar Immunoprofile With Other Tumors Harboring BCOR Genetic Alterations
All BCS tested showed nuclear positivity for BCOR (18/18) , typically with a strong and diffuse nuclear pattern (Fig. 5A) . BCOR expression was retained in the residual viable tumor in a postchemotherapy resection, showing > 90% tumor necrosis/fibrosis (Fig. 5B ). In addition, most tumors were positive for SATB2 (10/12, 83%), cyclin D1 (9/10, 90%), TLE1 (8/10, 80%), and Bcl-2 (7/7, 100%) (Figs. 5C-E). The consistent immunoreactivity for these markers matched the mRNA upregulation at gene expression level (data not shown). CD99 was only positive in about half of the cases (11/26, 42%) with variable intensity and extent. In addition, NTRK3 was identified as one of the differentially expressed genes in BCOR-CCNB3 tumors.
Distinctive HOX Gene Family Upregulation in Sarcomas With BCOR Genetic Alterations
By Affymetrix U133A array data analysis, BCS showed upregulation of multiple members of the HOX gene family, including HOXA, HOXB, HOXC, and to a lesser extent HOXD ( Supplementary Fig. 1 , Supplemental Digital Content 1, http://links.lww.com/PAS/A557). Some SS also showed HOX gene expression, especially for HOXD genes; whereas only occasional, nonrecurrent HOX gene expression was noted in the 4 ES samples. Using RNAseq data, we found that HOX genes were also upregulated in BCOR ITD tumors, especially for HOXA and HOXB, but not in CIC-rearranged sarcomas (Supplementary Fig. 1 , Supplemental Digital Content 1, http:// links.lww.com/PAS/A557). Overall, both BCS and BCOR ITD tumors showed distinctive overexpression of multiple HOX genes. Similar results were previously shown by our group in round cell sarcomas with BCOR-MAML3 fusion. 11 Furthermore, we obtained the individual gene expression signatures of BCS (249 genes), ES (93 genes), and SS (150 genes) from Affymetrix U133A array data, as described above. A Venn diagram showed an overlap of 11 genes between the 3 sarcoma types, including EZH2, WNT5A, and PMP2 (peripheral myelin protein 2), with most of the remaining genes representing distinctive signatures for each subtype (Fig. 6A) . Supervised clustering was performed using the BCS gene signature, showing distinctly separate groups of BCS, ES, and SS samples (Fig. 6B ).
BCSs have a Significantly Better Outcome than CIC-rearranged Sarcomas
Twenty-two BCS patients with available follow-up were analyzed and compared with previously published data sets of localized ES, CIC-rearranged sarcomas, and head and neck SS. 9, 10 The average follow-up duration of the study group was 38 months (range, 7 to 113 mo). All except 1 patient with available follow-up presented with localized disease at diagnosis, whereas the remaining patient (17/M) with a pubic ramus tumor and soft tissue extension was found to have a pancreatic metastasis at diagnosis. During the follow-up period, 6 patients developed local recurrence and 3 distant metastases (Table 1) . Metastatic sites included lung (n = 3), skull base, pelvis, scapula, and thigh (n = 1 each).
Of the 22 patients, 10 received neoadjuvant chemotherapy/chemoradiation followed by surgery, 7 had surgery followed by adjuvant chemotherapy, 1 chemotherapy, and 4 surgery alone. Most of the patients treated with chemotherapy were based on protocols for ES ( Table 1) . Seven of 9 patients treated with an ES chemotherapy regimen and evaluable histologic response showed significant treatmentrelated pathologic response (60% to 100% necrosis/fibrosis) in the posttherapy resection specimens. However, a recent case, not included in the survival analysis (case # 9), also treated with ES-based neoadjuvant chemotherapy, showed no response. The patient underwent partial foot resection/ray amputation and postoperative radiation therapy. Lung nodules were identified radiographically.
At last follow-up, 13 patients had no evidence of disease, 6 were alive with disease, 2 died of disease, and 1 died of an unknown cause. The 3-and 5-year survival rates were 93% and 72%, respectively. No significant prognostic difference was found in patients with mitotic rates ≥ 10/10 HPFs versus those with <10/10 HPFs (P = 1.000). Comparing these rates to the survival of ES, CIC-rearranged sarcomas, and SS (a head and neck cohort), a significant survival difference was noted (log-rank P < 0.0001), with CIC-rearranged sarcomas having the worst prognosis (Fig. 7) . BCS showed a significantly better prognosis than CIC-rearranged sarcomas (P = 0.005), whereas no statistical difference was noted between BCS and ES (P = 0.738) or between BCS and head and neck SS (P = 0.802).
DISCUSSION
In this study, we investigate a series of 36 BCS for their clinicopathologic features, including the morphologic spectrum and clinical outcome. Our results confirm the male predominance and predilection for older children and adolescents as the most commonly affected population. 1 In contrast to the initial report, our series reveals only a slight preference for skeletal (56%) over soft tissue (39%) locations, with equal distribution between axial sites and extremities. 1,2 Furthermore, although initially described as a prototypical round cell sarcoma, further evidence showed that common histologic features of BCS include a mixed round, ovoid to short spindle cell phenotype, arranged in fascicles or a whorling pattern, with often myxoid stroma, and arborizing capillary network. 2, 3, 5, 12, 13 In this series, 78% of cases showed a predominant round cell component, with most displaying, in addition, variable areas of ovoid to spindle tumor cells. The remaining 22% of cases showed predominantly monomorphic spindle cell features arranged in intersecting fascicles, reminiscent of MPNST or SS. Immunohistochemically, all tumors tested were positive for BCOR, whereas cyclin D1, SATB2, and TLE1 were also positive in the majority of cases. The morphologic spectrum and immunostaining profile highlight the significant overlap with other tumor entities sharing BCOR genetic alterations.
BCOR was first identified as a corepressor of BCL6, interacting with BCL6 through its N-terminal BCL6 binding domain. 14 Subsequently, BCOR was found to be a core component of a variant PRC1.1 complex associated with chromatin remodeling and histone modification. 15 As part of the PRC1.1 complex, the C-terminal BCOR PUFD domain binds to the RAWUL domain of PCGF1. 16 Of interest, all BCOR genetic abnormalities implicated in sarcomagenesis, including BCOR-CCNB3, BCOR-MAML3, and BCOR ITD, involve the last exon of BCOR, which encodes the PUFD domain. 16 Thus, the formation of gene fusions and ITD may alter the binding affinity between BCOR and PCGF1, affecting the subsequent recruitment by KDM2B, ubiquitinylation of H2AK119, and downstream gene regulation. 17 Additional fusions involving BCOR (ie, ZC3H7B-BCOR) have also been reported in endometrial stromal sarcomas and ossifying fibromyxoid tumors, where BCOR is often the 3' partner, contributing its exons 7 to 15. 18,19 BCOR-related translocations have also been described in hematoproliferative disorders involving different mechanisms, such as recurrent BCOR-RARA fusions (exon 12 of BCOR to exon 3 of RARA) in a small subset of acute promyelocytic leukemia; resulting chimeric transcripts lack the PUFD domain at the C-terminus. 20 BCOR inactivating mutations have also been identified in rhabdomyosarcomas and several hematologic malignancies, 21, 22 whereas germline BCOR mutation results in the oculofaciocardiodental syndrome. 23 CCNB3 is a relatively new member of the cyclin B family involved in cell cycle control, 24 being mainly expressed in the developing germ cells in the testis. The predicted BCOR-CCNB3 fusion oncoprotein retains the CCNB3 cyclin box, while lacking the N-terminal destruction box motif associated with CCNB3 degradation. 24 In adult human tissues, both BCOR and CCNB3 are expressed in the testis, 2, 25 indicating that they may have important function in germ cell survival or development. In BCS, CCNB3 expression is consistently upregulated. 1 Recent data from our group have suggested that undifferentiated sarcomas characterized by BCOR genetic alterations, spanning both gene fusions and ITD, share similarities at the morphologic and immunohistochemical level, despite the wide spectrum of clinical presentations and pathologic entities involved. 4, 25 Although our preliminary results suggest that infantile soft tissue undifferentiated round cell tumors (URCS) with BCOR ITD, primitive myxoid mesenchymal tumor of infancy (PMMTI), and clear cell sarcoma of the kidney (CCSK) represent a morphologic continuum of a single pathologic entity based on the shared genetic alterations, it is less certain if sarcomas with BCOR-related fusions, such as BCOR-CCNB3, also fit within this spectrum. The present study investigating the morphologic and immunohistochemical profile of a large group of BCS further emphasizes the similarities to the BCOR ITD genetic group, such as URCS, PMMTI, and CCSK. Despite their predilection for infants and soft tissue, infantile URCS with BCOR ITD or YWHAE fusions show striking morphologic overlap with BCS, including round to spindle cell morphology, fine chromatin pattern, rich capillary background, and myxoid stroma. 4 In addition, BCS and BCOR ITD tumors show an identical immunoprofile, with strong/diffuse reactivity for BCOR, SATB2, and cyclin D1 in the majority of cases. 6, 25 However, despite the close genomic grouping by RNAseq unsupervised clustering, BCOR ITD spectrum of tumors do not show CCNB3 mRNA expression, a common finding in BCS. Likewise, the 2 renal BCS reported by our group recently resemble CCSK, both morphologically and immunohistochemically. 6 Being the second most common pediatric renal tumor following Wilms tumor, CCSK typically shows uniform round to ovoid cells with fine chromatin separated by a rich vascular network and is characterized by BCOR ITD and BCOR upregulation in the majority of cases. 26 Nevertheless, CCSK mainly affects children between 2 and 4 years old, in contrast to the teenage group of BCS.
As the majority of BCS show some evidence of spindling, with 12% of BCS harboring a predominantly spindle cell fascicular growth, the differential diagnosis of BCS also includes spindle cell sarcomas, specifically monophasic SS, fibrosarcoma, and MPNST. In addition, half of SS are positive for BCOR, and both SS and BCS are immunopositive for TLE1. 25, 27 SATB2 reactivity, often expressed in BCS (80%), can also be detected in a small subset of SS (12%). 25 CCNB3 staining has been reported to be negative in SS, except nonspecific cytoplasmic staining in some cases. 5 A further pitfall was recently revealed in a SS18-negative spindle cell sarcoma showing diffuse BCOR expression and morphologically suspected to represent a BCOR-alteration sarcoma; however, RNAseq found a rare SS18L1-SSX variant fusion, diagnostic of SS. 7 Despite their similar clinical and demographic presentation, BCS shows histologic features distinctive from ES, including the more variable cytomorphology, from round, ovoid to spindle, common myxoid background and a rich capillary network. In contrast, ES is usually characterized by solid sheets of perfectly monomorphic round cells, ill-defined cell borders and fine chromatin, and the lack of significant stromal component. Immunohistochemically, ES shows consistent strong and diffuse CD99 membranous staining, which is much more variable in BCS. Cyclin D1 is expressed in both ES and BCS. 28 In contrast, strong and diffuse BCOR expression is the defining feature for BCS, while being only infrequently expressed in ES (1/9, 11%). 25 Another important differential diagnosis is with CIC-DUX4 fusion positive undifferentiated round cell sarcoma. In contrast to BCS, CIC-rearranged sarcomas typically affect young adults rather than children (mean age, 32) with no sex predilection. The overwhelming majority occur in soft tissue locations with infrequent intraosseous presentation. 9 Morphologically, CIC-rearranged sarcomas show a higher degree of nuclear variability, with prominent nucleoli and consistent immunoreactivity for ETV4 and WT1. 9, 29 As BCS often presents as an intraosseous lesion with a round cell/undifferentiated phenotype, expression of SATB2 might suggest an osteoblastic line of differentiation and be misinterpreted as a small cell osteosarcoma. Indeed 2 cases in this series were initially misdiagnosed as small cell OS involving femur and tibia, respectively, both locations being common for both diagnoses. 30 Osteoid or metaplastic bone formation in BCS is rare and so far only observed in metastatic lung lesions, including the case reported in our series. 2 Thus, our results point out that SATB2 expression is not specific for bone-forming tumors, and the immunowork-up of a skeletal round cell malignancy should include, in addition to SATB2, other markers such as BCOR and cyclin D1 to exclude a BCS diagnosis.
The RNAseq data from the 4 BCS cases and the publicly available expression array data from the Pierron et al 1 study revealed significant mRNA upregulation of NTRK3 in BCS, which was also confirmed in a subset of our cases at the protein level (data not shown). The mechanism of NTRK3 mRNA upregulation remains unclear. Similar NTRK3 overexpression is also observed in the infantile URCS with BCOR ITD (data not shown).
Besides the morphologic differences between BCS and other undifferentiated round to spindle cell sarcomas, such as ES, CIC-rearranged sarcomas, and SS, our study also addressed their clinical behavior. Previous studies suggested a 5-year OS rate of 75% for BCS, with axial location, local recurrence, and metastasis being poor prognostic factors. 2, 12 In patients with localized disease, induction therapy with ES-based protocols was associated with a better outcome. 12 The OS of BCS reported in a small series of 10 patients (6 with localized stage at presentation) was not statistically different from an ES cohort. 2 However, no prior studies have compared the outcome of BCS with CIC-rearranged sarcomas or SS, 2 pathologic entities commonly included in the differential diagnoses. Our study analyzed the clinical outcome of 22 BCS patients (mean follow-up, 38 mo) showing that the OS of BCS (3-year, 93%; 5-year, 72%), is superior to CI-C-rearranged sarcomas, whereas not statistically different from ES and SS. Given that these retrospective cohorts were composed of patients treated nonuniformly in different institutions, further investigation of patients with matched risk factors, disease stages, and uniform treatment protocols would be needed to confirm this finding. An additional point of investigation was assessing the pathologic response of BCS tumors to the applied neoadjuvant chemotherapy regimens. As BCS was originally classified among ES family of tumors, most patients have been managed so far with ES-related chemotherapy protocols. Two previous studies have suggested that BCS are chemoresponsive 2, 12 ; 1 study showing a good histologic response ( > 90% necrosis) in 77% (10/13) of the evaluable patients treated mainly with ES chemotherapy but also other regimens. 12 In another study, 4 of the 6 postchemotherapy resections showed complete response, whereas the remaining 2 had scattered residual tumor cells. 2 Our study has further investigated the extent of tumor response in 9 resection specimens treated with ES regimens, showing 5 of the 9 patients with > 90% necrosis and 2 of the 9 patients with 60-90 % necrosis. Of note, other tumors with oncogenic BCOR upregulation, for example CCSK, have been treated with somewhat different chemotherapy regimens, which usually do not include ifosfamide as in most ES regimens. 31, 32 Given the overlapping morphology and transcriptional profile of BCS and CCSK and given that CCSK has shown sensitivity to doxorubicin-based chemotherapy, 32, 33 it remains to be determined whether BCS patients might also benefit from an overall less toxic protocol compared with the presently applied ES-based regimens (doxorubicin and ifosfamide combination). Another consideration is that CCSK are well known to relapse many (over 10) years after diagnosis, mandating long-term follow-up for these children. Given the genetic relatedness of BCS and CCSK, it is possible that BCS patients may relapse late too, though there is little data to address this concern at this time.
As indicated by previous microarray data analysis 1 and our RNAseq hierarchical clustering, BCS showed a distinct transcriptional profile compared with ES. This study further demonstrated the BCS expression signature is similar to tumors harboring BCOR ITD and BCOR-MAML3, with a significant upregulation of HOX (homeobox) family genes. 1, 11 HOX genes encode a group of transcription factors responsible for embryo development, including anterior-posterior body axis, and adult fracture healing process. 34, 35 HOX abnormalities have also been reported in various cancer types, including carcinomas of breast, colon, prostate, and lung. 36 In sarcomas, overexpression of HOX genes has been reported in ES, 34 but restricted to HOXD genes, which was not observed in our 4 ES samples. In addition, WNT and Hedgehog signaling pathways are similarly activated in both BCS and BCOR ITD tumors of central nervous system. 1, 37, 38 In conclusion, we report a large series of 36 BCS, highlighting the significant morphologic, immunohistochemical and transcriptional overlap with other primitive round/spindle cell sarcomas with BCOR gene alterations, despite differences in their demographics and clinical presentations. Our results also show that BCS have histologic features, immunoprofile, and expression signatures that are distinct from other common round cell sarcomas, such as ES and CIC-DUX4 tumors. Emerging evidence suggests that most BCS tumors are chemosensitive to ESbased therapy protocols, although other less toxic regimens currently applied in CCSK might also be investigated. Lastly, the OS rate of BCS is significantly more favorable than CIC-rearranged sarcomas, but appears similar to ES and SS though long-term follow-up may be needed.
